Literature DB >> 33680951

FOXM1 and Cancer: Faulty Cellular Signaling Derails Homeostasis.

Dhanya Kalathil1, Samu John1,2, Asha S Nair1,2.   

Abstract

Forkhead box transcription factor, FOXM1 is implicated in several cellular processes such as proliferation, cell cycle progression, cell differentiation, DNA damage repair, tissue homeostasis, angiogenesis, apoptosis, and redox signaling. In addition to being a boon for the normal functioning of a cell, FOXM1 turns out to be a bane by manifesting in several disease scenarios including cancer. It has been given an oncogenic status based on several evidences indicating its role in tumor development and progression. FOXM1 is highly expressed in several cancers and has also been implicated in poor prognosis. A comprehensive understanding of various aspects of this molecule has revealed its role in angiogenesis, invasion, migration, self- renewal and drug resistance. In this review, we attempt to understand various mechanisms underlying FOXM1 gene and protein regulation in cancer including the different signaling pathways, post-transcriptional and post-translational modifications. Identifying crucial molecules associated with these processes can aid in the development of potential pharmacological approaches to curb FOXM1 mediated tumorigenesis.
Copyright © 2021 Kalathil, John and Nair.

Entities:  

Keywords:  FOXM1; cell signaling; miRNA; post-transcriptional regulation; post-translational regulation

Year:  2021        PMID: 33680951      PMCID: PMC7927600          DOI: 10.3389/fonc.2020.626836

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  17 in total

1.  FOXM1 Promotes Malignant Proliferation of Esophageal Squamous Cell Carcinoma Through Transcriptional Activating CDC6.

Authors:  Xiongfeng Chen; Jingbo Chen; Xunbin Yu; Guishan Lin; Ting Chen
Journal:  DNA Cell Biol       Date:  2022-05-30       Impact factor: 3.550

2.  Estrogen Receptor-Regulated Gene Signatures in Invasive Breast Cancer Cells and Aggressive Breast Tumors.

Authors:  Emily Smart; Svetlana E Semina; Luis H Alejo; Nidhi S Kansara; Jonna Frasor
Journal:  Cancers (Basel)       Date:  2022-06-09       Impact factor: 6.575

Review 3.  A narrative review of research progress on FoxM1 in breast cancer carcinogenesis and therapeutics.

Authors:  Yan-Ling Zhang; Yan Ma; You-Qin Zeng; Yan Liu; En-Ping He; Yi-Tong Liu; Feng-Ling Qiao; Rong Yu; Ying-Shuang Wang; Xin-Yu Wu; Ping Leng
Journal:  Ann Transl Med       Date:  2021-11

4.  FDI-6 inhibits the expression and function of FOXM1 to sensitize BRCA-proficient triple-negative breast cancer cells to Olaparib by regulating cell cycle progression and DNA damage repair.

Authors:  Shu-Ping Wang; Shi-Qi Wu; Shi-Hui Huang; Yi-Xuan Tang; Liu-Qiong Meng; Feng Liu; Qi-Hua Zhu; Yun-Gen Xu
Journal:  Cell Death Dis       Date:  2021-12-08       Impact factor: 8.469

5.  HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation.

Authors:  Alessandra Leone; Alfredo Budillon; Maria Serena Roca; Tania Moccia; Federica Iannelli; Cristina Testa; Carlo Vitagliano; Michele Minopoli; Rosa Camerlingo; Giulia De Riso; Rossella De Cecio; Francesca Bruzzese; Mariarosaria Conte; Lucia Altucci; Elena Di Gennaro; Antonio Avallone
Journal:  J Exp Clin Cancer Res       Date:  2022-03-03

6.  Berberine Inhibits FOXM1 Dependent Transcriptional Regulation of POLE2 and Interferes With the Survival of Lung Adenocarcinoma.

Authors:  Lulu Ni; Ping Sun; Xiaochun Fan; Zhongjie Li; Hongli Ren; Jiangan Li
Journal:  Front Pharmacol       Date:  2022-01-31       Impact factor: 5.810

Review 7.  Targeting Ribosome Biogenesis to Combat Tamoxifen Resistance in ER+ve Breast Cancer.

Authors:  Ho Tsoi; Chan-Ping You; Man-Hong Leung; Ellen P S Man; Ui-Soon Khoo
Journal:  Cancers (Basel)       Date:  2022-02-28       Impact factor: 6.639

8.  CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition.

Authors:  David Gallo; Jordan T F Young; Jimmy Fourtounis; Giovanni Martino; Alejandro Álvarez-Quilón; Cynthia Bernier; Nicole M Duffy; Robert Papp; Anne Roulston; Rino Stocco; Janek Szychowski; Artur Veloso; Hunain Alam; Prasamit S Baruah; Alexanne Bonneau Fortin; Julian Bowlan; Natasha Chaudhary; Jessica Desjardins; Evelyne Dietrich; Sara Fournier; Chloe Fugère-Desjardins; Theo Goullet de Rugy; Marie-Eve Leclaire; Bingcan Liu; Vivek Bhaskaran; Yael Mamane; Henrique Melo; Olivier Nicolas; Akul Singhania; Rachel K Szilard; Ján Tkáč; Shou Yun Yin; Stephen J Morris; Michael Zinda; C Gary Marshall; Daniel Durocher
Journal:  Nature       Date:  2022-04-20       Impact factor: 49.962

9.  The human ion channel TRPM2 modulates cell survival in neuroblastoma through E2F1 and FOXM1.

Authors:  Iwona Hirschler-Laszkiewicz; Fernanda Festa; Suming Huang; George-Lucian Moldovan; Claudia Nicolae; Ashna Dhoonmoon; Lei Bao; Kerry Keefer; Shu-Jen Chen; Hong-Gang Wang; Joseph Y Cheung; Barbara A Miller
Journal:  Sci Rep       Date:  2022-04-15       Impact factor: 4.996

Review 10.  FOXM1: A Multifunctional Oncoprotein and Emerging Therapeutic Target in Ovarian Cancer.

Authors:  Cassie Liu; Carter J Barger; Adam R Karpf
Journal:  Cancers (Basel)       Date:  2021-06-19       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.